Drugs

HTA ID	Drug	Brand	Indication	Assessment status	Date
21055	Relugolix with estradiol and norethisterone acetate	Ryeqo®	Is indicated for moderate to severe symptoms of uterine fibroids in adult women of reproductive age.	Rapid Review Complete	3rd February 2022
24018	Relugolix with estradiol and norethisterone acetate	Ryeqo®	Relugolix with estradiol and norethisterone acetate (Ryeqo®) is Indicated in adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.	Awaiting full HTA submission from Applicant	18th February 2025
-	Reslizumab	Cinqaero®	Is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.	Rapid Review Complete	1st March 2017
-	Retigabine	Trobalt®	Cost-effectiveness of Retigabine (Trobalt®)	Rapid Review Complete	6th April 2011
24007	Rezafungin	Rezzayo®	Rezafungin (Rezzayo®) is indicated for the treatment of invasive candidiasis in adults.	Rapid Review Complete	11th March 2025
-	Ribociclib	Kisqali®	In combination with an aromatase inhibitor (AI) is indicated for the treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine based therapy.	Assessment Process Complete	13th August 2018
-	Ribociclib	Kisqali®	Is indicated in combination with an aromatase inhibitor or fulvestrant for the treatment of pre-, peri- and post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine therapy, or in women who have received prior endocrine therapy:	Rapid Review Complete	11th July 2019
24045	Ribociclib	Kisqali®	Ribociclib in combination with an aromatase inhibitor (AI) is indicated for the adjuvant treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence.	Rapid Review Complete	19th December 2024
-	Rifaximin	Targaxan®	Is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age.	Rapid Review Complete	7th August 2013
-	Rilpivirine	Edurant®	In combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml.	Rapid Review Complete	6th January 2012
-	Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF)	Odefsey®	For the treatment of adults and adolescents (≥ 12 years, body weight ≥35 kg) infected with HIV 1 without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/ml.	Rapid Review Complete	13th July 2016
22051	Rimegepant	Vydura®	Rimegepant (Vydura®) for the treatment of acute migraine with or without aura and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.	NCPE Assessment Process complete	11th March 2025
-	Rimonabant	Acomplia®	For the management of multiple cardiovascular risks in overweight or obese patients in Ireland	Assessment Process Complete	16th October 2006
-	Riociguat	Adempas®	For the treatment of Pulmonary arterial hypertension (PAH) and Chronic thromboembolic pulmonary hypertension (CTEPH).	Rapid Review Complete	20th May 2014
23061	Risankizumab	Skyrizi®	Risankizumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. The Applicant is seeking reimbursement in a subgroup of the licensed population, as second-line treatment after failure of the first biologic therapy.	NCPE Assessment Process Complete	5th June 2024
22038	Risankizumab	Skyrizi®	Alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).	Rapid Review Complete	30th June 2022
24025	Risankizumab	Skyrizi®	For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional or biologic therapy. The Applicant is seeking reimbursement in a subgroup of the licensed population, as second-line treatment after failure of the first biologic therapy.	Rapid Review Complete	6th August 2024
19010	Risankizumab	Skyrizi®	Is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.	Assessment Process Complete	12th August 2021
21006	Risdiplam	Evrysdi™	For the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.	NCPE Assessment Process Complete	20th October 2023
23071	Ritlecitinib	Litfulo®	For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.	Full HTA submission received from Applicant	11th February 2025
-	Rituximab	MabThera®	Is indicated in adults for Non-Hodgkin’s lymphoma (NHL): Is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy: As maintenance therapy for the treatment of follicular lymphoma patients responding to induction therapy: For the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.	Rapid Review Complete	24th September 2014
-	Rivaroxaban	Xarelto®	Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.	Rapid Review Complete	22nd November 2017
-	Rivaroxaban	Xarelto®	For the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.	Assessment Process Complete	18th June 2019
-	Rivaroxaban	Xarelto®	For the prevention of stroke in atrial fibrillation.	Assessment Process Complete	19th June 2012
-	Rivaroxaban	Xarelto®	For the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Total Hip Replacement or Total Knee Replacement.	Full HTA Assessment	18th September 2008
-	Rivaroxaban	Xarelto®	For the Treatment of Deep Vein Thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults.	Assessment Process Complete	24th February 2012
-	Rivaroxaban	Xarelto®	Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.	Rapid Review Complete	22nd November 2017
-	Roflumilast	Daxas®	For the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations.	Full HTA Assessment	3rd November 2010
-	Rolapitant	Varuby®	For the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.	Rapid Review Complete	13th June 2017
-	Romiplostim	Nplate®	Is indicated for chronic immune (idiopathic) thrombocytopenic purpura (ITP) in patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).	Rapid Review Complete	19th July 2019
-	Romiplostim	Nplate®	Is indicated for the treatment of adult chronic ITP splenectomised patients who have had either an inadequate response or who are intolerant of corticosteroids and immunoglobulins and also as second line treatment for adult ITP non-splenectomised patients where surgery is contraindicated.	Rapid Review Complete	27th May 2015
21016	Romosozumab	Evenity®	For the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.	NCPE Assessment Process Complete	11th March 2025
23004	Ropeginterferon alfa-2b	Besremi®	Ropeginterferon alfa-2b is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.	NCPE Assessment Process Complete	15th August 2024
-	Ropivacaine Readyfusor®	Ropivacaine Readyfusor®	For acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion.	Rapid Review Complete	13th December 2018
21037	Roxadustat	Evrenzo™	For the treatment of adult patients with symptomatic anaemia associated with chronic kidney disease.	Rapid Review Complete	6th October 2021
-	Ruxolitinib	Jakavi®	For the treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.	Assessment Process Complete	9th July 2013
20008	Ruxolitinib	Jakavi®	For the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.	Assessment Process Complete	21st July 2021
25004	Ruxolitinib	Opzelura®	Ruxolitinib (Opzelura®) is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.	Rapid Review Complete	17th February 2025
22007	Sacituzumab govitecan	Trodelvy®	Is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, including at least one of them for advanced disease.	NCPE Assessment Process Complete	24th March 2023
23079	Sacituzumab govitecan	Trodelvy®	Sacituzumab govitecan is indicated for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.	Rapid Review Complete	26th January 2024
-	Sacubitril/valsartan	Entresto®	For the treatment of symptomatic chronic heart failure with reduced ejection fraction if adult patients.	Assessment Process Complete	8th July 2016
-	Safinamide methansulfonate	Xadago®	For the treatment of adult patients with idiopathic Parkinson’s disease.	Rapid Review Complete	6th July 2016
-	Sapropterin	Kuvan®	For the treatment of phenylketonuria (PKU).	Full HTA Assessment	15th September 2017
-	Sarilumab	Kevzara®	In combination with methotrexate (MTX) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARD). Sarilumab can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.	Rapid Review Complete	4th October 2017
-	Sebelipase alfa	Kanuma®	Is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.	Assessment Process Complete	8th June 2018
-	Secukinumab	Cosentyx®	For the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy	Rapid Review Complete	16th December 2015
-	Secukinumab	Cosentyx®	For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.	Assessment Process Complete	16th September 2015
-	Secukinumab	Cosentyx®	Alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.	Rapid Review Complete	16th December 2015
-	Selexipag	Uptravi®	For the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.	Assessment Process Complete	21st May 2018
21020b	Selpercatinib	Retsevmo®	For the treatment of adult patients with advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with lenvatinib and/or sorafenib.	Awaiting HTA submission from Applicant	7th July 2021